Cardiovascular mechanisms of SSRI drugs and their benefits and risks in ischemic heart disease and heart failure

International Clinical Psychopharmacology

Volumn 28, Issue 3, 2013, Pages 145-155

  Chittaranjan, Andrade ^a   Chethan, Kumar B ^a   Sandarsh, Surya ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

cardiovascular disease; heart failure; ischemic heart disease; platelets; selective serotonin reuptake inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CITALOPRAM; CLOPIDOGREL; FLUOXETINE; FLUVOXAMINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; NORTRIPTYLINE; PAROXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; VASCULAR CELL ADHESION MOLECULE 1; ZOLMITRIPTAN;

CARDIOVASCULAR PARAMETERS; CATABOLISM; COMORBIDITY; CONGESTIVE HEART FAILURE; DEPRESSION; DRUG MECHANISM; ELECTROCARDIOGRAPHY; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART HEMODYNAMICS; HEART PROTECTION; HEART RATE VARIABILITY; HUMAN; IN VITRO STUDY; ISCHEMIC HEART DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SEROTONIN BLOOD LEVEL; STRESS; TREATMENT RESPONSE; VARIANT ANGINA PECTORIS;

BLOOD PRESSURE; HEART FAILURE; HEART RATE; HUMANS; MYOCARDIAL ISCHEMIA; RISK ASSESSMENT; SEROTONIN UPTAKE INHIBITORS;

EID: 84875814451     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32835d735d     Document Type: Review

References (69)

1. Acikel S, Dogan M, Sari M, Kilic H, Akdemir R (2010). Prinzmetal-variant angina ina patient using zolmitriptan and citalopram. Am J Emerg Med 28:e3-e6.
2. Alvarez JC, Gluck N, Fallet A, Grégoire A, Chevalier JF, Advenier C, et al. (1999).Plasma serotonin level after 1 day of fluoxetine treatment: a biologicalpredictor for antidepressant response? Psychopharmacology (Berl)143:97-101.
3. Andrade C, Sandarsh S, Chethan KB, Nagesh KS (2010). Serotonin reuptakeinhibitor antidepressants and abnormal bleeding: a review for clinicians and areconsideration of mechanisms. J Clin Psychiatry 71:1565-1575.
4. Bakkaloglu B, Yabanoglu S, özyüksel BR, Uc ar G, Ertugrul A, Demir B, et al.(2008). Platelet and plasma serotonin levels and platelet monoamine oxidaseactivity in patients with major depression: effects of sertraline treatment. TurkJ Biochem 33:97-103.
5. Berkman LF, Blumenthal J, Burg M, Carney RM, Catellier D, Cowan MJ, et al.Enhancing Recovery in Coronary Heart Disease Patients Investigators(ENRICHD) (2003). Effects of treating depression and low perceived socialsupport on clinical events after myocardial infarction: the Enhancing Recoveryin Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA289:3106-3116.
6. Blanchette CM, Simoni-Wastila L, Shaya FT, Orwig D, Noel J, Stuart B (2009).Depression following thrombotic cardiovascular events in elderly medicarebeneficiaries: risk of morbidity and mortality. Cardiol Res Pract 2009:1-8.
7. Carney RM, Blumenthal JA, Stein PK, Watkins L, Catellier D, Berkman LF, et al.(2001). Depression, heart rate variability, and acute myocardial infarction.Circulation 104:2024-2028.
8. Cohen HW, Gibson G, Alderman MH (2000). Excess risk of myocardial infarctionin patients treated with antidepressant medications: association with use oftricyclic agents. Am J Med 108:2-8.
9. Davidson KW, Rieckmann N, Clemow L, Schwartz JE, Shimbo D, Medina V, et al.(2010). Enhanced depression care for patients with acute coronarysyndrome and persistent depressive symptoms: coronary psychosocialevaluation studies randomized controlled trial. Arch Intern Med 170:600-608.
10. Dhaenen H (2001). Imaging the serotonergic system in depression. Eur ArchPsychiatry Clin Neurosci 251:1176-1180.
11. Dowlati Y, Herrmann N, Swardfager WL, Reim EK, Lancttt KL (2010). Efficacyand tolerability of antidepressants for treatment of depression in coronaryartery disease: a meta-analysis. Can J Psychiatry 55:91-99.
12. Fosbol EL, Gislason GH, Poulsen HE, Hansen ML, Folke F, Schramm TK, et al.(2009). Prognosis in heart failure and the value of {beta}-blockers are alteredby the use of antidepressants and depend on the type ofantidepressants used. Circ Heart Fail 2:582-590.
13. Glassman AH, Shapiro PA (1998). Depression and the course of coronary arterydisease. Am J Psychiatry 155:4-11.
14. Glassman AH, Bigger JT Jr, Gaffney M (2009). Psychiatric characteristicsassociated with long-term mortality among 361 patients having an acutecoronary syndrome and major depression: seven-year follow-up of SADHARTparticipants. Arch Gen Psychiatry 66:1022-1029.
15. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT Jr, et al. Sertraline antidepressant heart attack randomized trial (SADHART)group (2002). Sertraline treatment of major depression in patients with acuteMI or unstable angina. JAMA 288:701-709.
16. Golding M, Kotlyar M, Carson SW, Hoyler S, Lazarus C, Davidson C, et al.(2005). Effects of paroxetine on cardiovascular response to mental stress insubjects with a history of coronary artery disease and no psychiatricdiagnoses. Psychopharmacology (Berl) 182:321-326.
17. Gulliksson M, Burell G, Vessby B, Lundin L, Toss H, Svdrdsudd K (2011).Randomized controlled trial of cognitive behavioral therapy vs standardtreatment to prevent recurrent cardiovascular events in patients with coronaryheart disease: Secondary Prevention In Uppsala Primary Health Care Project(SUPRIM). Arch Intern Med 171:134-140.
18. Habra ME, Baker B, Frasure-Smith N, Swenson JR, Koszycki D, Butler G, et al.(2010). First episode of major depressive disorder and vascular factors incoronary artery disease patients: baseline characteristics and response toantidepressant treatment in the CREATE trial. J Psychosom Res 69:133-141.
19. Halperin D, Reber G (2007). Influence of antidepressants on hemostasis.Dialogues Clin Neurosci 9:47-59.
20. Hippisley-Cox J, Pringle M, Hammersley V, Crown N, Wynn A, Meal A, et al.(2001). Antidepressants as risk factor for ischaemic heart disease: case-control study in primary care. BMJ 323:666-669.
21. Hong E, Castillo C, Flores E, Mercedes F (1994). Serotoninergic receptors andcardiovascular diseases. Gac Med Mex 130:131-133.
22. Ishida T, Hirata K, Sakoda T, Kanazawa K, Kawashima S, Akita H, et al. (1998).5-HT1D beta receptor mediates the supersensitivity of isolated coronaryartery to serotonin in variant angina. Chest 113:243-244.
23. Ishida T, Kawashima S, Hirata Ki, Sakoda T, Shimokawa Y, Miwa Y, et al. (2001).Serotonin-induced hypercontraction through 5-hydroxytryptamine 1Breceptors in atherosclerotic rabbit coronary arteries. Circulation 103:1289-1295.
24. Jiang W, Glassman A, Krishnan R, O'Connor CM, Califf RM (2005) Depressionand ischemic heart disease: what have we learned so far and what must wedo in the future? Am Heart J 150:54-78.
25. Kemp AH, Quintana DS, Gray MA, Felmingham KL, Brown K, Gatt J (2010).Impact of depression and antidepressant treatment on heart rate variability:a review and meta-analysis. Biol Psychiatry 67:1067-1074.
26. Konig F, Hdfele M, Hauger B, Lvble M, Wvssner S, Wolfersdorf M (1996).Bradycardia after beginning therapy with metoprolol and paroxetine [inGerman]. Psychiatr Prax 23:244-245.
27. Leftheriotis D, Flevari P, Ikonomidis I, Douzenis A, Liapis C, Paraskevaidis I, et al.(2010). The role of the selective serotonin re-uptake inhibitor sertralinein nondepressive patients with chronic ischemic heart failure: a preliminarystudy. Pacing Clin Electrophysiol 33:1217-1223.
28. Lekakis J, Ikonomidis I, Papoutsi Z, Moutsatsou P, Nikolaou M, Parissis J, et al.(2010). Selective serotonin re-uptake inhibitors decrease the cytokineinducedendothelial adhesion molecule expression, the endothelial adhesivenessto monocytes and the circulating levels of vascular adhesion molecules.Int J Cardiol 139:150-158.
29. Le Quan-Bui KH, Plaisant O, Leboyer M, Kamal L, Devynck MA, Meyer P (1984).Reduced platelet serotonin in depression. Psychiatry Res 13:129-139.
30. Macchia A, Monte S, Pellegrini F, Romero M, D'Ettorre A, Tavazzi L, et al. (2008).Depression worsens outcomes in elderly patients with heart failure: ananalysis of 48, 117 patients in a community setting. Eur J Heart Fail 10:714-721.
31. MacDonald TM, McMahon AD, Reid IC, Fenton GW, McDevitt DG (1996).Antidepressant drug use in primary care: a record linkage study in Tayside, Scotland. BMJ 313:860-861.
32. Mazza M, Lotrionte M, Biondi-Zoccai G, Abbate A, Sheiban I, Romagnoli E (2010). Selective serotonin reuptake inhibitors provide significant lower rehospitalizationrates in patients recovering from acute coronary syndromes:evidence from a meta-analysis. J Psychopharmacol 24:1785-1792.
33. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, et al. (2010).Reduced-function CYP2C19 genotype and risk of adverse clinical outcomesamong patients treated with clopidogrel predominantly for PCI: a metaanalysis.JAMA 304:1821-1830.
34. Meier CR, Schlienger RG, Jick H (2001). Use of selective serotonin reuptakeinhibitors and risk of developing first-time acute myocardial infarction. Br JClin Pharmacol 52:179-184, 84.
35. Monster TB, Johnsen SP, Olsen ML, McLaughlin JK, Sxrensen HT (2004).Antidepressants and risk of first-time hospitalization for myocardial infarction:a population-based case-control study. Am J Med 117:732-737.
36. Monte S, Macchia A, Romero M, D'Ettorre A, Giuliani R, Tognoni G (2009).Antidepressants and cardiovascular outcomes in patients without knowncardiovascular risk. Eur J Clin Pharmacol 65:1131-1138.
37. Nemeroff CB, Knight DL, Franks J, Craighead WE, Krishnan KR (1994). Furtherstudies on platelet serotonin transporter binding in depression. Am JPsychiatry 151:1623-1625.
38. O'Connor CM, Jiang W, Kuchibhatla M, Mehta RH, Clary GL, Cuffe MS, et al.(2008). Antidepressant use, depression, and survival in patients with heartfailure. Arch Intern Med 168:2232-2237.
39. O'Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, et al.(2010). Safety and efficacy of sertraline for depression in patients with heartfailure: results of the SADHART-CHF (Sertraline Against Depression andHeart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol 56:692-699.
40. Pizzi C, Mancini S, Angeloni L, Fontana F, Manzoli L, Costa GM (2009). Effects ofselective serotonin reuptake inhibitor therapy on endothelial function andinflammatory markers in patients with coronary heart disease. Clin PharmacolTher 86:527-532.
41. Pizzi C, Rutjes AWS, Costa GM, Fontana F, Mezzetti A, Manzoli L (2011). Metaanalysisof selective serotonin reuptake inhibitors in depression and coronaryheart disease. Am J Cardiol 107:972-979.
42. Pollock BG, Laghrissi-Thode F, Wagner WR (2000). Evaluation of plateletactivation in depressed patients with ischemic heart disease after paroxetineor nortriptyline treatment. J Clin Psychopharmacol 20:137-140.
43. Raeder MB, Bjelland I, Emil Vollset S, Steen VM (2006). Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: the HordalandHealth Study. J Clin Psychiatry 67:1974-1982.
44. Ramasubbu R (2004). Cerebrovascular effects of selective serotonin reuptakeinhibitors: a systematic review. J Clin Psychiatry 65:1642-1653.
45. Roose SP, Glassman AH, Attia E, Woodring S, Giardina EG, Bigger JT Jr (1998).Cardiovascular effects of fluoxetine in depressed patients with heart disease.Am J Psychiatry 155:660-665.
46. Rosenberg LB, Whang W, Shimbo D, Shah A, Shapiro PA, Davidson KW (2010).Exposure to tricyclic antidepressants is associated with an increased risk ofincident CHD events in a population-based study. Int J Cardiol 145:124-125.
47. Santangelo A, Testal M, Barbagallo P, Crisafulli C, Grasso S, Manuele S, et al.(2009). Use of specific serotonin reuptake inhibitors (SSRIs) (Sertraline orCitalopram) in the treatment of depression reduces the cardiovascular risk inthe elderly: evidence from a Sicilian population >80 years recovered in theassisted sanitary residences (RSA). Arch Gerontol Geriatr 48:350-352.
48. Sauer WH, Berlin JA, Kimmel SE (2001). Selective serotonin reuptake inhibitorsand myocardial infarction. Circulation 104:1894-1898.
49. Sauer WH, Berlin JA, Kimmel SE (2003). Effect of antidepressants and theirrelative affinity for the serotonin transporter on the risk of myocardialinfarction. Circulation 108:32-36.
50. Schins A, Honig A, Crijns H, Baur L, Hamulyak K (2003) Increased coronaryevents in depressed cardiovascular patients: 5-HT2A receptor asmissing link? Psychosom Med 65:729-737.
51. Schlienger RG, Fischer LM, Jick H, Meier CR (2004). Current use of selectiveserotonin reuptake inhibitors and risk of acute myocardial infarction. Drug Saf27:1157-1165.
52. Serebruany VL (2006) Selective serotonin reuptake inhibitors and increasedbleeding risk: are we missing something? Am J Med 119:113-116.
53. Serebruany VL, Gurbel PA, O'Connor CM (2001). Platelet inhibition by sertralineand N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptakeinhibitors. Pharmacol Res 43:453-462.
54. Serebruany VL, Glassman AH, Malinin AI, Atar D, Sane DC, Oshrine BR, et al.(2003a). Selective serotonin reuptake inhibitors yield additional antiplateletprotection in patients with congestive heart failure treated with antecedentaspirin. Eur J Heart Fail 5:517-521.
55. Serebruany VL, Glassman AH, Malinin AI, Nemeroff CB, Musselman DL, van ZylLT, et al. Sertraline antidepressant heart attack randomized trial study group(2003b). Platelet/endothelial biomarkers in depressed patients treated withthe selective serotonin reuptake inhibitor sertraline after acute coronaryevents: the sertraline antidepressant heart attack randomized trial (SADHART)platelet substudy. Circulation 108:939-944.
56. Serebruany VL, Suckow RF, Cooper TB, O'Connor CM, Malinin AI, Krishnan KR, et al. Sertraline antidepressant heart attack randomized trial (2005).Relationship between release of platelet/endothelial biomarkers and plasmalevels of sertraline and N-desmethylsertraline in acute coronary syndromepatients receiving SSRI treatment for depression. Am J Psychiatry162:1165-1170.
57. Sheline YI, Bardgett ME, Jackson JL, Newcomer JW, Csernansky JG (1995).Platelet serotonin markers and depressive symptomatology. Biol Psychiatry37:442-447.
58. Smoller JW, Allison M, Cochrane BB, Curb JD, Perlis RH, Robinson JG, et al.(2009). Antidepressant use and risk of incident cardiovascular morbidity andmortality among postmenopausal women in the Women's HealthInitiative study. Arch Intern Med 169:2128-2139.
59. Strik JJ, Honig A, Lousberg R, Cheriex EC, Van Praag HM (1998). Cardiacside-effects of two selective serotonin reuptake inhibitors in middle-agedand elderly depressed patients. Int Clin Psychopharmacol 13:263-267.
60. Strik JJ, Honig A, Lousberg R, Lousberg AH, Cheriex EC, Tuynman-Qua HG, et al.(2000). Efficacy and safety of fluoxetine in the treatment of patients withmajor depression after first myocardial infarction: findings from a doubleblind, placebo-controlled trial. Psychosom Med 62:783-789.
61. Swenson JR, Doucette S, Fergusson D (2006). Adverse cardiovascular events inantidepressant trials involving high-risk patients: a systematic review ofrandomized trials. Can J Psychiatry 51:923-929.
62. Tata LJ, West J, Smith C, Farrington P, Card T, Smeeth L, et al. (2005). Generalpopulation based study of the impact of tricyclic and selective serotoninreuptake inhibitor antidepressants on the risk of acute myocardial infarction.Heart 91:465-471.
63. Taylor CB, Youngblood ME, Catellier D, Veith RC, Carney RM, Burg MM, et al. (2005).Effects of antidepressant medication on morbidity and mortality in depressedpatients after myocardial infarction. Arch Gen Psychiatry 62:792-798.
64. Thayer JF, Yamamoto SS, Brosschot JF (2010). The relationship of autonomicimbalance, heart rate variability and cardiovascular disease risk factors. Int JCardiol 141:122-131.
65. Tiihonen J, Lvnnqvist J, Wahlbeck K, Klaukka T, Tanskanen A, Haukka J (2006).Antidepressants and the risk of suicide, attempted suicide, and overallmortality in a nationwide cohort. Arch Gen Psychiatry 63:1358-1367.
66. Tousoulis D, Antoniades C, Drolias A, Stefanadi E, Marinou K, Vasiliadou C, et al.(2008). Selective serotonin reuptake inhibitors modify the effect of betablockerson long-term survival of patients with end-stage heart failure andmajor depression. J Card Fail 14:456-464.
67. Tseng YL, Chiang ML, Huang TF, Su KP, Lane HY, Lai YC (2010). A selectiveserotonin reuptake inhibitor, citalopram, inhibits collagen-induced plateletaggregation and activation. Thromb Res 126:517-523.
68. Xiong GL, Jiang W, Clare R, Smith PK, Mahaffey KW, O'Connor CM, et al.(2006). Prognosis of patients taking selective serotonin reuptake inhibitorsbefore coronary artery bypass grafting. Am J Cardiol 98:42-47.
69. Ziegelstein RC, Meuchel J, Kim TJ, Latif M, Alvarez W, Dasgupta N, et al. (2007).Selective serotonin reuptake inhibitor use by patients with acute coronarysyndromes. Am J Med 120:525-530.